I concur with many of the comments here, especially considering...

I concur with many of the comments here, especially considering the number of shares currently in issue. This stock has experienced some significant highs and now some cumulative lows. The dedication and expertise of our team is the reason we are all here. It has been a long journey for them, refining the science year after year to reach our current position.

As I mentioned in my previous post, it is worth monitoring our counterpart, as we are already ahead with patient enrollment and are halfway through our Phase 2 study. While our CEO prefers having capital in the bank and has previously opted for capital raises, I am pleased that this time they chose a placement of 75,220,800 shares sold on the market at $0.0054 . I agree with Gordan2020's comment regarding the $0.07 options. Reviewing the recent announcements on options and their expiry dates is insightful. I appreciate that they opted for market sales, and I believe maintaining price consistency is crucial. Following the last readout, purchasing at $0.005 or $0.25 presents an exciting opportunity for a speculative stock in early-stage dementia treatment.

https://www.marketindex.com.au/asx/ath/announcements/options-prospectus-3A640497

https://www.marketindex.com.au/asx/ath/announcements/notification-regarding-unquoted-securities-ath-3A645077


I hope they refrain from raising funds between now and the Phase 2 study readout. If the data is positive and we progress to a potential Phase 3 study, a minor capital raise would be understandable. Ideally, six months into the Phase 3 study, with more definitive data, we could consider a 20-1 consolidation along with a possible capital raise. Regardless, our share register reflects a strong foundation. If everything proceeds as planned, it's just a matter of determining the final valuation.

It could also be worth noting that if the trial ends in November, it would be prudent to keep an eye on any new substantial holders between October and January.